Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | BCL6 | P41182 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.40 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024594 | 0.85 | CYP19A1 (0.60) | CYP19A1TP53NTRK1POLBTNNI3K | |
| SCHEMBL2514436 | 0.85 | NTRK1 (0.51) | CYP19A1NTRK1POLBBCL6CDC25A | |
| SCHEMBL1025031 | 0.84 | POLB (0.53) | CYP19A1POLBBCL6JAK1HDAC1 | |
| SCHEMBL1073861 | 0.80 | MAP3K8 (0.46) | NTRK1BCL6 | |
| SCHEMBL1026771 | 0.79 | CTSC (0.47) | NTRK1BCL6JAK1 | |
| SCHEMBL4175833 | 0.78 | BCL6 (0.56) | BCL6JAK1LMNA | |
| SCHEMBL1024074 | 0.78 | MET (0.44) | NTRK1BCL6BRD4CDC25ACDC25B | |
| SCHEMBL1026333 | 0.78 | AURKA (0.47) | ROCK1NTRK1BRD4LMNA | |
| SCHEMBL1023956 | 0.77 | BCL6 (0.42) | NTRK1BCL6JAK1 | |
| SCHEMBL30306511 | 0.76 | BRD4 (0.63) | JAK1HDAC1BRD4TNNI3KLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CYP19A1 2565/4885TP53 805/4885ROCK1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.